Guselkumab shows significant clinical and endoscopic benefits for adults with moderate to severe Crohn disease, offering a ...

Common unpleasant symptoms after eating too much of the wrong thing happen to just about anyone. Cramping, nausea, abdominal pain or gas typically don't last long, but if you have Crohn's ...

When it comes to Inflammatory Bowel Disease, or IBD, Australia is a world leader — with the number of people living here with ...

YUFLYMA® (adalimumab-aaty) is a high-concentration (100mg/mL) and citrate-free formulation of Humira® (adalimumab) biosimilar ...

A man with Crohn’s disease has called on Sainsbury’s to reopen toilets in its Bromley superstore, saying people like him are ...

French biotech moves on with the late stage drug development, after publishing impressive clinical trial results of ABX464 for treatment of colitis and hinting its potential in Crohn’s disease.

The pause of billions of dollars in research funding to universities has had devastating effects on cancer research as lab work is put on hold and schools are halting the acceptance of new Ph.D.

Want to know what the future holds? You need to meet the people building it. In our series Who’s Next, we profile rising ...

While all the recent chatter around colon cancer is alarming, new studies are also showing promising data around the positive ...